The Executive Diagnostic and Governance Toolkit
Biotech Research Prioritization for Chief Science Officers
Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which research pipeline to prioritize for clinical trials and defend the choice to stakeholders.
Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.
| 1 |
You stop guessing where you stand. You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis. |
| 2 |
You can defend the decision. You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language. |
| 3 |
The work actually moves. The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total. |
| 4 |
You use it the day it lands. No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over. |
The situation this is built for
Every day, chief science officers face pressure to select one research pipeline over others—each with promising data, passionate advocates, and uncertain outcomes. The decision must balance scientific rigor, clinical feasibility, resource constraints, and strategic alignment. Without a consistent framework, these choices rely too heavily on intuition or incomplete data, leaving leaders vulnerable when questioned by executives, board members, or regulatory partners. The cost of a misstep is measured not just in dollars, but in delayed therapies and lost scientific momentum.
Who this is for
Chief science officers in biotechnology organizations who own pipeline selection and must defend those decisions in cross-functional leadership meetings and board reviews.
Who this is not for
This is not for lab managers, clinical operations staff, or external consultants who do not own the final decision on research prioritization.
What you walk away with
- A standardized framework for comparing research pipelines
- Clear documentation of decision criteria and trade-offs
- Improved alignment between R&D and executive leadership
- Greater confidence in go/no-go recommendations
- Efficient integration of preclinical data into strategic decisions
How this maps to your situation
- Assessing current decision processes
- Identifying data gaps in pipeline evaluations
- Aligning team members on evaluation criteria
- Preparing for upcoming portfolio reviews
Before vs. after
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 3 hours per module, designed to be completed at your pace over 8–12 weeks, with immediate access to implementation tools.
How this compares to the alternatives
Unlike general project management courses or scientific training programs, this course focuses exclusively on the decision architecture required for biotechnology pipeline prioritization—providing field-specific frameworks, real-world templates, and actionable playbooks tailored to the responsibilities of a chief science officer.
Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)
Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.
- Understanding the role of the chief science officer in pipeline governance
- Mapping the lifecycle of a biotechnology research program
- Defining key decision points from discovery to clinical proposal
- Identifying internal and external stakeholders in pipeline reviews
- Recognizing common cognitive biases in research selection
- Balancing innovation potential with technical feasibility
- Aligning pipeline decisions with organizational mission and capacity
- Documenting assumptions behind early-stage research interpretations
- Setting expectations for data completeness in preclinical packages
- Integrating safety signals from in vitro and animal models
- Assessing novelty versus incremental advancement in target selection
- Creating a decision accountability framework for leadership
- Assessing target-disease association using genetic evidence
- Interpreting functional genomics data in target validation
- Evaluating on-target versus off-target effects in model systems
- Reviewing dose-response relationships in pharmacological assays
- Mapping pathway conservation across species for translatability
- Assessing redundancy in biological signaling networks
- Determining biomarker linkage to mechanism of action
- Evaluating target engagement data from biochemical assays
- Weighing evidence from loss-of-function versus gain-of-function studies
- Integrating CRISPR screening results into target confidence scores
- Assessing compensatory mechanisms in knockout models
- Documenting confidence levels in mechanistic hypotheses
- Evaluating experimental design in animal efficacy studies
- Assessing statistical power and sample size justification
- Identifying signs of publication bias in literature reviews
- Reviewing blinding and randomization procedures in reports
- Detecting data dredging in biomarker correlation analyses
- Validating assay performance characteristics in study data
- Assessing batch-to-batch variability in compound synthesis
- Evaluating pharmacokinetic parameters for consistency
- Reviewing histopathology data with blinded interpretation
- Assessing duration of effect in chronic disease models
- Identifying overfitting in machine learning-based predictions
- Creating a data quality checklist for internal studies
- Estimating first-in-human dosing from toxicology data
- Assessing route of administration challenges for novel modalities
- Evaluating formulation stability and shelf-life implications
- Determining patient recruitment feasibility for rare indications
- Mapping clinical endpoints to measurable biological changes
- Assessing monitoring requirements for safety-intensive therapies
- Reviewing comparator arm availability for trial design
- Evaluating duration of treatment in chronic conditions
- Assessing need for specialized clinical sites or equipment
- Identifying regulatory precedents for similar mechanisms
- Determining biomarker qualification status for use in trials
- Balancing endpoint sensitivity with real-world measurement
- Creating weighted scoring models for multi-parameter evaluation
- Integrating cytokine release risk into early safety profiles
- Assessing immunogenicity potential of biologic candidates
- Evaluating biodistribution patterns in tissue targeting
- Balancing potency against narrow therapeutic windows
- Incorporating off-tumor effects in oncology pipelines
- Assessing germline editing risks in gene therapy programs
- Mapping metabolic clearance pathways for toxicity risks
- Weighing long-term safety monitoring needs in trial planning
- Integrating reproductive toxicity findings into risk profiles
- Evaluating depot formation risks in sustained-release formulations
- Documenting risk mitigation strategies for high-concern liabilities
- Mapping candidate alignment with company therapeutic focus
- Assessing competitive pipeline intelligence for timing decisions
- Evaluating freedom-to-operate considerations in target selection
- Analyzing patent life and exclusivity windows for development paths
- Assessing platform synergy across multiple programs
- Determining resource overlap in manufacturing infrastructure
- Evaluating platform scalability for future pipeline expansion
- Balancing platform investment against discrete product returns
- Assessing potential for combination therapy positioning
- Reviewing market access considerations in indication selection
- Evaluating orphan drug designation opportunities
- Assessing payer willingness to reimburse novel mechanisms
- Structuring data packages for executive committee review
- Summarizing key uncertainties for leadership discussion
- Creating visual summaries of comparative pipeline performance
- Preparing Q&A briefs for board-level inquiries
- Aligning medical affairs input on unmet need definitions
- Incorporating regulatory affairs feedback on development paths
- Integrating biostatistics input on trial powering assumptions
- Reviewing CMC constraints with manufacturing leadership
- Assessing budget impact with finance stakeholders
- Documenting decision rationale for audit readiness
- Ensuring legal review of claims in decision documents
- Standardizing presentation formats across pipeline reviews
- Applying GRADE principles to preclinical evidence grading
- Creating evidence maps for transparent data visualization
- Assigning confidence levels to different data types
- Resolving contradictions between in vitro and in vivo results
- Integrating real-world evidence into preclinical assessments
- Evaluating animal model limitations for human prediction
- Weighing case reports versus controlled study findings
- Assessing reproducibility across independent laboratories
- Incorporating negative data into overall assessments
- Using Bayesian reasoning to update confidence over time
- Documenting evidence gaps in candidate profiles
- Creating summary statements for non-scientific audiences
- Translating mechanism of action for executive understanding
- Explaining risk-benefit trade-offs in non-technical terms
- Anticipating board questions about competitive positioning
- Presenting alternative scenarios in decision discussions
- Using analogies to explain complex biological concepts
- Preparing for challenges to data interpretation
- Communicating uncertainty without undermining confidence
- Aligning messaging across leadership spokespersons
- Responding to inquiries about failed predecessors
- Defining success criteria for early clinical milestones
- Explaining go/no-go thresholds to investor-facing teams
- Maintaining scientific integrity under commercial pressure
- Designing quarterly pipeline review meeting structures
- Setting data triggers for re-evaluation decisions
- Defining decision authority levels across stages
- Creating audit trails for major selection decisions
- Incorporating external advisory board input systematically
- Scheduling external benchmarking assessments
- Reviewing portfolio balance across therapeutic areas
- Assessing talent availability for specialized programs
- Evaluating infrastructure readiness for scale-up
- Updating risk profiles with new preclinical findings
- Incorporating regulatory feedback into go/no-go planning
- Managing sunset decisions for terminated pipelines
- Assessing equity in patient access to novel therapies
- Evaluating potential for therapeutic misconception in trials
- Considering long-term societal impact of gene editing
- Balancing aggressive timelines with thorough safety assessment
- Assessing environmental impact of manufacturing processes
- Evaluating dual-use potential of platform technologies
- Considering implications for germline transmission risks
- Addressing concerns about enhancement versus therapy
- Incorporating patient advocacy perspectives in selection
- Assessing global health relevance of indication choices
- Evaluating potential for medicalization of normal conditions
- Documenting ethical review considerations in decision logs
- Creating standardized templates for pipeline dossiers
- Training team members on evidence grading frameworks
- Establishing data quality thresholds for advancement
- Documenting institutional risk tolerance profiles
- Developing onboarding materials for new science leaders
- Integrating decision frameworks into project management tools
- Creating archival systems for historical decision context
- Scheduling calibration sessions across research teams
- Implementing feedback loops from clinical outcomes
- Updating decision criteria based on portfolio experience
- Aligning performance metrics with long-term success
- Sustaining scientific rigor amid organizational growth
Frequently asked
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
Thousands of organisations have bought from The Art of Service since 2000.